This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Incyte Corp's Phase 3 results of LBA-1 Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma, as discussed at the ASH Annual Meeting.
Ticker(s): INCYWho's the expert?
Institution: University of Texas Southwestern Medical Center
- Hematopathologist affiliated with UT Southwestern Medical Center
- Research interests include atherosclerosis, thrombosis, vascular biology, lipid metabolism, GVHD, molecular pathogenesis of lymphoma and leukemia, tumor immunology, viral infections and cancergenesis
- Published over 90 peer reviewed papers, 120 abstracts and 11 book chapters
- Manages 45 patients with PNH and has prescribed Epaveli
Interview GoalThis conversation will focus on the current treatment landscape and potential use of LBA-1 Tafasitamab for follicular lymphoma.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
